A subgroup analysis included 1095 patients with tumor size ranging from 1 to 10 mm, and Trastuzumab was shown to significantly reduce the risk of recurrence even in small HER2+ breast cancer patients (HR 0.61, 95%CI 0.38–0.99). The gene discussed is ERBB2; the disease is neoplasm.